Research summary ·
Clinical Outcomes of the Germline RET M918T Pathogenic Variant in Hereditary Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review pooled cohort studies of a gene change called RET M918T. It looked at people with hereditary medullary thyroid cancer. The review compared them with people who had other RET changes. It covered 1485 people. The team pooled odds ratios for several outcomes. These were spread to lymph nodes or other organs, advanced stage and death. The search ran to May 2026.
What they found
The M918T change was linked to higher odds of lymph node spread. The odds ratio was 7.86, with a range of 2.58 to 23.94. It was also linked to spread to other organs, at 6.50. Advanced-stage disease had an odds ratio of 4.88. Death had an odds ratio of 7.32. The link looked stronger for death from the cancer than for death from any cause. That gap was not statistically significant.
What it means for patients
The authors say M918T was linked to worse outcomes than other RET changes.
Why it is not certain yet
The comparison groups were mixed. Other factors may still distort the results. The authors say this rules out a cause-and-effect reading. Sample sizes varied by outcome.
Source
Clinical Outcomes of the Germline RET M918T Pathogenic Variant in Hereditary Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
PubMed · PMID 42796243We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Neuroendocrine tumours publications